NCT03550508View on ClinicalTrials.gov

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

August 30, 2019

Study Completion Date

December 1, 2019

Conditions
Bone Metastases
Interventions
BIOLOGICAL

Anti-RANKL Monoclonal Antibody

JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.

Trial Locations (1)

200123

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

collaborator

Covance

INDUSTRY

collaborator

KingMed Diagnostics

UNKNOWN

lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT03550508 - Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors | Biotech Hunter | Biotech Hunter